Artelo Biosciences (ARTL) Change in Accured Expenses (2014 - 2025)
Artelo Biosciences (ARTL) posted quarterly Change in Accured Expenses of -$832000.0 for Q4 2025, down 285.3% year-over-year from $449000.0 in Q4 2024, and up 8.17% quarter-over-quarter from -$906000.0 in Q3 2025.
Artelo Biosciences (ARTL) Change in Accured Expenses (2014 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Change in Accured Expenses for 12 consecutive years, with -$832000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Accured Expenses fell 285.3% year-over-year to -$832000.0; the TTM figure through Dec 2025 stood at $1.3 million (up 191.31% YoY), while the FY2025 annual figure was $1.3 million, up 191.31% from the prior year.
- Change in Accured Expenses rose to -$832000.0 in Q4 2025 per ARTL's latest filing, from -$906000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.2 million in Q2 2025 and bottomed at -$906000.0 in Q3 2025.
- Historically, Change in Accured Expenses has averaged $127023.3 across 5 years, with a median of $121710.0 in 2021.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 1836.84% — and 2025, when it plunged 346.2%.
- Artelo Biosciences' Change in Accured Expenses stood at $132000.0 in 2021, then surged by 318.18% to $552000.0 in 2022, then plunged by 33.33% to $368000.0 in 2023, then climbed by 22.01% to $449000.0 in 2024, then tumbled by 285.3% to -$832000.0 in 2025.
- Business Quant data shows ARTL's Change in Accured Expenses at -$832000.0 in Q4 2025, -$906000.0 in Q3 2025, and $2.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | -832,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -832,000.00 |
| Dec 31, 2025 | -832,000.00 |
| Sep 30, 2025 | -906,000.00 |
| Sep 30, 2025 | -906,000.00 |
| Jun 30, 2025 | 2.25 Mn |
| Jun 30, 2025 | 2.25 Mn |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 449,000.00 |
| Dec 31, 2024 | 449,000.00 |
| Sep 30, 2024 | 368,000.00 |
| Sep 30, 2024 | 368,000.00 |
| Jun 30, 2024 | 256,000.00 |
| Jun 30, 2024 | 256,000.00 |
| Mar 31, 2024 | -624,000.00 |
| Mar 31, 2024 | -624,000.00 |
| Dec 31, 2023 | 368,000.00 |
| Dec 31, 2023 | 368,000.00 |
| Sep 30, 2023 | 330,000.00 |
| Sep 30, 2023 | 330,000.00 |